Over the last few years, various monoclonal antibodies targeting immunological checkpoints such as CTLA-4, PD-1, and PD-L1 have been approved, each with its own mode of action. Manufacturers are concentrating their efforts on creating medications from many classifications to treat various disorders, from cancer to rare diseases. Monoclonal antibodies combined with chemotherapeutic drugs are increasingly being used to treat various malignancies. For instance, the United States Food and Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone in 2017 to treat patients with multiple myeloma who had previously received two treatments.
